FDA ClinicalTrials.gov Report Will Show Growing Rate Of Study Listings
This article was originally published in The Pink Sheet Daily
Executive Summary
The forthcoming report also will show increased disclosure of company sponsors and drug names in trial descriptions. FDA has added language to IND acknowledgement letters to promote compliance with listing requirements.